Rise In Securities Class Action Filings In Life Sciences Sector
Last year proved to be another record period for securities class actions, with a 13% increase in cases filed compared with 2018, and a 24% increase in claims brought against life sciences companies compared with 2018, according to a report by Cornerstone Research: Securities Class Action Filings: 2019 Year In Review.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."